Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bexarotene + Sargramostim in MDS and AML
NCT00425477Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Nov 2006
- Primary completion
- Sep 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of bexarotene in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Nov 2006; status: completed.
02
Drugs
bexarotene
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00425477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00425477.